- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Dr Bertossi on the Prognostic Role of TP53 Mutations in CLL
June 15th 2024, 1:50pm
European Hematology Association Congress
Consuelo Bertossi, MD, discusses the role of TP53 mutations and their prognostic significance in chronic lymphocytic leukemia.
Dr Grunwald on the Rates of Disease Progression in Low-Risk Myelofibrosis
June 15th 2024, 1:46pm
European Hematology Association Congress
Michael R. Grunwald, MD, FACP, discusses disease progression in patients with low-risk myelofibrosis enrolled in the prospective MOST study.
Zanubrutinib Plus Obinutuzumab/Venetoclax Is Safe, Elicits Responses in Older Patients With Untreated MCL
June 15th 2024, 1:11pm
European Hematology Association Congress
The combination of zanubrutinib, obinutuzumab, and venetoclax was safe and well-tolerated in older patients with untreated mantle cell lymphoma.
Earlier Use of Acalabrutinib Associated With Improved Survival in CLL
June 14th 2024, 8:14pm
European Hematology Association Congress
Earlier use of acalabrutinib was associated with improved survival in patients with chronic lymphocytic leukemia.
CAR T-Cell Therapy Is Safe, Feasible in Outpatient Setting for NHL
June 14th 2024, 7:59pm
European Hematology Association Congress
The administration of CAR T-cell therapy in the outpatient setting was deemed feasible and safe in patients with relapsed/refractory NHL.
Ponatinib Regimen Shows Long-term Efficacy in Acute Lymphoblastic Leukemia
June 14th 2024, 7:53pm
European Hematology Association Congress
Ponatinib, chemo, and alloHSCT offer long-term survival in adult Ph+ ALL, per 4-year PONALFIL trial data at 2024 EHA Congress.
Englumafusp alfa/Glofitamab Combo Shows Early Responses in R/R Aggressive non-Hodgkin Lymphoma
June 14th 2024, 7:18pm
European Hematology Association Congress
Englumafusp alfa plus glofitamab showed activity and tolerability in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.
Anemia Does Not Diminish Benefit With Ruxolitinib Treatment in Myelofibrosis
June 14th 2024, 6:52pm
European Hematology Association Congress
Patients with new or worsening anemia from their myelofibrosis did not experience lessened clinical benefit of ruxolitinib treatment.
CD7-Directed CAR T-Cell Therapy WU-CART-007 Is Safe in R/R T-ALL/LBL
June 14th 2024, 6:36pm
European Hematology Association Congress
The CD7-targeted CAR T-cell therapy WU-CART-007 had a manageable safety profile and elicited preliminary efficacy signals in relapsed/refractory T-ALL/LBL.
Frontline Blinatumomab Demonstrates “Impressive” Activity in Down Syndrome B-ALL
June 14th 2024, 6:12pm
European Hematology Association Congress
Blinatumomab consolidation improved MRD clearance over chemotherapy in DS B-ALL patients, according to ALLTogether1 DS study results.
Disease Duration, Elevated WBC Count, and VAF Predict Disease Progression in Polycythemia Vera
June 14th 2024, 6:11pm
European Hematology Association Congress
Time from diagnosis, elevated WBC count, and VAF were all significantly associated with an increased risk of disease progression of polycythemia vera.
Dr Kamdar on Results From a Subgroup Analysis of Liso-Cel in MCL
June 14th 2024, 6:03pm
European Hematology Association Congress
Manali Kamdar, MD, discusses the results of the phase 3 TRANSFORM trial in relapsed/refractory large B-cell lymphoma (LBCL) that were presented during the 2021 ASH Annual Meeting & Exposition.
Dr Aldoss on Responses With WU-CART-007 After Enhanced Lymphodepletion in R/R T-ALL/LBL
June 14th 2024, 5:59pm
European Hematology Association Congress
Ibrahim Aldoss, MD, discusses the impact of enhanced lymphodepletion on responses with WU-CART-007 in relapsed/refractory T-ALL/LBL.
HOVON-146 Study Shows Blinatumomab Boosts B-ALL Outcomes
June 14th 2024, 5:47pm
European Hematology Association Congress
HOVON-146 showed integrating blinatumomab into pre-phase and consolidation therapy improved outcomes in newly diagnosed B-ALL.
Observational Study Finds Progression Common in Lower-Risk Myelofibrosis
June 14th 2024, 5:20pm
European Hematology Association Congress
Over a 4-year period, most patients with lower-risk myelofibrosis experienced disease progression, according to the prospective MOST study.
Liso-Cel Associated With Improved Benefit in Earlier Lines of Therapy in R/R Mantle Cell Lymphoma
June 14th 2024, 4:49pm
European Hematology Association Congress
Clinically meaningful activity was found across all subgroups in a posthoc subgroup analysis of patients with MCL treated with liso-cel.
Zanubrutinib Plus Venetoclax Generates 100% ORR in Treatment-Naive Del17p/TP53+ CLL/SLL
June 14th 2024, 4:45pm
European Hematology Association Congress
Zanubrutinib/venetoclax elicited a 100% overall response rate in untreated chronic lymphocytic leukemia harboring 17p deletions or TP53 mutations.
Ide-Cel Generates Favorable PFS Outcomes in R/R Multiple Myeloma With Lower Tumor Burden
June 14th 2024, 3:20pm
European Hematology Association Congress
Ide-cel induced improved PFS outcomes in patients with relapsed/refractory multiple myeloma with characteristics including lower tumor burden.
Talquetamab Produces Responses in R/R Myeloma After Prior T-Cell–Directed Therapies
June 12th 2024, 1:44pm
Talquetamab proved safe and effective for relapsed/refractory myeloma, even in patients with comorbidities.
Lurbinectedin Plus Irinotecan Is Safe, Prolongs Responses in High-Risk, Pretreated SCLC
June 11th 2024, 9:00pm
Clinical benefit generated from treatment with lurbinectedin plus irinotecan was noted across sensitive and resistant patient populations with SCLC.